FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports

The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week.